Ify Osunkwo

Ify Osunkwo

Chief Patient Officer, Novo Nordisk Rare Disease
Boston, Massachusetts, United States

*50 free lookup(s) per month.

No credit card required.

Ify Osunkwo’s Email

Ify Osunkwo’s Phone Numbers

Social Media

Ify Osunkwo’s Location

Ify Osunkwo’s Current Industry

Ify Osunkwo’s Prior Industry

Not the Ify Osunkwo you were looking for?

Find accurate emails & phone numbers for over 700M professionals.

🔍 Search

Work Experience

Novo Nordisk

Chief Patient Officer, Novo Nordisk Rare Disease

2022-10-01 - Present

Patient-Centered Outcomes Research Institute (PCORI) Grant on Improving Transition for EA-SCD

Principal Investigator

2017-09-01 - Present

Atrium Health

mPI Sickle Cell Trevor Thompson Transition (ST3P-UP) Study

2017-03-01 - Present

Forma Therapeutics

Chief Patient Officer, SVP

2022-02-01 - 2022-10-01

MDEdge

Editor In Chief; Hematology News

2020-01-01 - 2022-02-01

National Academy of Sports Medicine (NASM)

Commitee Member; National Academy of Science Engineering and Medicine Sickle Cell Study

2019-04-01 - 2020-08-01

Health Resources and Services Administration (HRSAgov), HHS

mPrinciple Investigator EMBRACE SCD Network; HRSA - Southeast SCDTDP

2017-09-01 - 2022-02-01

University of North Carolina at Chapel Hill

Clinical Associate Professor Of Medicine

2014-02-01 - 2019-10-01

Children's Healthcare of Atlanta

Director of Clinical Operations, Sickle Cell Program @ Egleston

2006-08-01 - 2013-08-01

Emory University School of Medicine

Assistant Professor of Pediatrics

2005-01-01 - 2013-08-01

Rutgers Cancer Institute of New Jersey

Assistant Director of Clinical Services, Pediatrics Sickle Cell Program

2003-08-01 - 2004-12-01

Columbia University Vagelos College of Physicians and Surgeons

Post Doctoral Clinical Fellow Pediatric Blood and Marrow Transplantation Fellowship

2002-07-01 - 2003-06-01

Rutgers New Jersey Medical School

Pediatric Resident

1997-07-01 - 2000-06-01

University of Nigeria, Nsukka

Rotating Internship, University of Nigeria Teaching Hospital

1994-01-01 - 1995-01-01

Skills

biotechnology life sciences pharmaceuticals insulin obesity rare diseases diabetes

Languages

English